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The effects of 8-year pamidronate treatment on skeletal morbidity 
in patients with advanced multiple myeloma
Maria Kraj, Ryszard Pog∏ód, Stanis∏aw Maj, Jan Pawlikowski
B a c k g r o u n d.  In patients with multiple myeloma (MM) osteolytic bone destruction progresses despite a reduction of
tumor mass achieved with chemotherapy. The aim of the study was to evaluate the efficacy of pamidronate, an inhibitor of
osteoclastic bone resorption administered to MM patients receiving anti-myeloma chemotherapy acc. to the VMCP/VBAP
alternating regimen.
M a t e r i a l  a n d  m e t h o d.  46 patients with stage III myeloma and osteolytic lesions received either pamidronate (Aredia;
Novartis) 60 mg i.v. in 4 – hour infusions monthly (n=23) or chemotherapy alone (control group n=23).
Re s u l t s.  On comparison of consecutive skeletal X- ray surveys performed after 6, 12, 18, 24, 30, 36, 42, 48, 54 and 66 cycles
of pamidronate the progression of osteolysis was respectively found in 67%, 39%, 27%, 20%, 25%, 25%, 60%, 80%, 92%
and 96% of patients. In the control group the corresponding figures were: 79%, 70%, 30%, 44%, 50%, 40%, 66% and 100%
(p>0,16). Median time to the occurrence of the first skeletal-related event was 13 months in the pamidronate group and 7
months in the control group. The mean number of skeletal events (pathologic fractures, radiation or surgery of bones and spinal
cord compression) per year in the first 4 years of treatment was 1.42 in the pamidronate group and 1.96 in the control
group. During further treatment these values reached 0.51 vs 0.9, respectively (p=0.08). At the end of the 8 years the
proportion of patients who had developed skeletal events (excluding vertebral fractures) was lower in the pamidronate group
as compared to the control group – 52% vs 56%, respectively (p=0.42). The ratio of patients with vertebral pathologic
fractures was identical – 76% vs 75%, but the number of vertebral fractures was lower in the pamidronate group than in the
control group – 50 vs 71, respectively (1.2 vs 1.77 per year in the first 4 years p=0.07 and 0.84 vs 0.91 in the next 4 years of
treatment). During the 4 latter years of study decreases of the blood hemoglobin level occurred with the same frequency among
the pamidronate patients and in controls. No significant differences of patient survival were observed between the pamidronate
group and the control group (median: 21 vs 20 months from randomization, p= 0.78 and median: 50 vs 45 months since MM
diagnosis, p= 0.20). 5-year and 8-year survival was 48% and 30%, respectively, for patients receiving pamidronate, as
compared to 17% and 13%, respectively for patients receiving chemotherapy only.
C o n c l u s i o n s.  Long-term pamidronate treatment moderately reduces myeloma-related skeletal morbidity. As the treatment
duration lengthens the effect of pamidronate on skeletal morbidity becomes less pronounced and the difference in the
incidence of anaemia between the pamidronate group and the controls is much less distinct.
Wp∏yw 8-letniego leczenia pamidronianem powik∏aƒ kostnych w zaawansowanym szpiczaku plazmocytowym
C e l.  U chorych na szpiczaka plazmocytowego (sz.p.) mimo redukcji masy nowotworowej pod wp∏ywem chemioterapii
destrukcja osteolityczna cz´sto post´puje. Celem pracy by∏a ocena skutecznoÊci pamidronianu, inhibitora osteoklastycznej
resorpcji kostnej u chorych na sz.p. z osteolizà, w III okresie choroby.
M a t e r i a ∏  i m e t o d y.  46 chorych otrzymujàcych chemioterapi´ przeciwnowotworowà VMCP/VBAP randomizowano:
23 w∏àczono do leczenia pamidronianem (Aredia) 60 mg i.v. comiesi´cznie, tak˝e 23 chorych, stanowiàcych grup´ kontrolnà,
pozostawiono wy∏àcznie na chemioterapii.
W y n i k i.  W badaniu radiologicznym koÊçca przeprowadzonym po 6, 12, 18, 24, 30, 36, 42, 48, 54 i 66 cyklach pamidronia-
nu, porównujàc obraz ka˝dego kolejnego badania z poprzednim, progresj´ osteolizy stwierdzono odpowiednio u: 67%, 39%,
27%, 20%, 25%, 25%, 60%, 80%, 92% i 96% chorych. W grupie kontrolnej progresja osteolizy wystàpi∏a odpowiednio u:
79%, 70%, 30%, 44%, 50%, 40%, 66% i 100% chorych (p>0,16). Mediana czasu do wystàpienia pierwszego powik∏ania
kostnego wynosi∏a w grupie leczonej pamidronianem 13 miesi´cy, a w grupie kontrolnej 7 miesi´cy. Ârednia liczba powik∏aƒ
kostnych na rok by∏a mniejsza w grupie leczonej pamidronianem (w pierwszych 4 latach leczenia 1,42 vs 1,96, w póêniejszych
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Introduction
Multiple myeloma is characterized by the accumulation of
malignant plasma cells in the bone marrow and by
osteolytic bone destruction, which is responsible for
increased morbidity and mortality. Skeletal destruction
results from increased osteoclastic activity, which is not
accompanied by a comparable increase in bone formation
and is mediated by cytokines, which are produced locally
in the bone marrow microenvironment by either myeloma
cells or stromal cells. The interaction of plasma cells with
stromal cells in the bone marrow microenvironment is
crucial for the activation of osteoclasts [1]. Apart from
cytokines, such as interleukin-6 (IL-6), IL-1β, IL-11 and
the tumour necrosis factors (TNFs), which are known to
have osteoclast activating properties, the identification
of new molecules, such as the receptor activator of nu-
clear factor-kappa β (RANK), its ligand (RANKL), osteo-
protegerin (OPG; the decoy receptor of RANKL),
macrophage inflammatory protein-1 alpha (MIP-1α) and
vascular endothelial growth factor (VEGF) has provided
new insight into the pathogenesis of multiple myeloma
bone disease. Inhibition of OPG production by myeloma
cells associated with increased expression of RANKL in
the bone marrow disrupt RANKL/OPG ratio in favor of
the osteoclastogenic factor RANKL. The main role of
the RANKL/OPG axis deregulation in multiple myelo-
ma–induced osteolysis is highlighted by the high potency
of RANKL inhibitors such as OPG or RANK-Fc to
prevent both excessive osteoclast development and lytic
bone lesion appearance in different murine myeloma
models [2]. VEGF is a multifunctional cytokine that plays
a role in angiogenesis and tumour neovascularization,
and has recently been implicated as a mediator of osteo-
clastogenesis in multiple myeloma. VEGF is expressed
by myeloma cells and it binds to the receptor, VEGFR-1,
that is predominantly expressed on osteoclasts. VEGF
directly enhances osteoclastic bone resorption and
survival of mature osteoclasts [3].
In multiple myeloma patients new bone formation is
reduced and bone lesions usually do not heal even in
patients with complete remission of the proliferative
process. This suggests that a functional defect of
osteoblasts is also important in the lytic process. Indeed,
the number and function of osteoblasts are decreased in
myeloma with osteolytic lesions. Recently Tian et al. [4]
have reported the production of the potential osteoblast
inhibitor DKK1 by myeloma cells. Actually, DKK1 can
block Wnt signaling, an important pathway involved in
osteoblast differentiation and function, and its over-
expression in multiple myeloma is associated with lytic
bone disease.
Bisphosphonates inhibit osteoclastic bone resorption
by inhibiting osteoclastic recruitment and maturation,
inducing osteoclast apoptosis, and interrupting their
attachment to the bone. They also induce apoptosis of
human multiple myeloma cells, [5] reduce IL-6 secretion
by bone marrow stromal cells, and cause expansion of γδ
T-cells with anti-multiple myeloma activity, suggesting
a possible anti-myeloma effect of these agents [6]. It has
been reported that pamidronate has either direct or
indirect anti-tumour effect in patients with multiple
myeloma [7]. Interestingly, it has been recently shown
that both pamidronate and zoledronic acid stimulate
OPG production by primary human osteoblasts [8].
The second-generation aminobisphosphonate,
pamidronate, has been shown to reduce skeletal events,
including pathologic fractures [9, 10] and to decrease
bone resorption markers in multiple myeloma patients
[11, 12].
In the Warsaw Institute of Haematology and Blood
Transfusion the efficacy of pamidronate was being
evaluated in multiple myeloma patients since October
1995. The results of the first twenty once-monthly cycles
of pamidronate demonstrated its effectiveness in the
prevention and treatment of hypercalcaemia, hyper-
calciuria and bone pain [13, 14]. The results obtained
during a median 48 month pamidronate treatment were
presented at the 28th World Congress of the International
Society of Hematology, at the 6th Annual Meeting of the
European Haematology Association and at the XX
Congress of the Polish Society of Haematology and Blood
Transfusion [15] and are the subject of this paper.
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latach 0,51 vs 0,9; p=0,08). Pod koniec 8-letnich badaƒ ∏àczny odsetek chorych, u których wystàpi∏y powik∏ania kostne, nie
ró˝ni∏ si´ w obu grupach (52% vs 56%; p= 0,42). Odsetek chorych z patologicznymi z∏amaniami kr´gów by∏ identyczny w obu
grupach 76% vs 75%, natomiast liczba z∏amaƒ kr´gów by∏a mniejsza w grupie pamidronianowej, wynoszàc odpowiednio
50 vs 71 (1,2 vs 1,77 na rok w pierwszych 4 latach, p=0,07 i 0,84 vs 0,91 w póêniejszych latach). W ciàgu ostatnich 4 lat ba-
daƒ niedokrwistoÊç wyst´powa∏a z takà samà cz´stotliwoÊcià u chorych leczonych pamidronianem co w grupie kontrolnej.
W grupie pamidronianowej mediana prze˝ycia wynosi 21 miesi´cy od randomizacji i 50 miesi´cy od rozpoznania sz.p.,
a w grupie kontrolnej 20 miesi´cy od randomizacji i 45 miesi´cy od rozpoznania sz.p. (p=0,78; p=0,20). W grupie pamidro-
nianowej 5 i 8-letnie prze˝ycia wynosi∏y odpowiednio 48% i 30%, a w grupie kontrolnej odpowiednio 17% i 13%.
W n i o s k i.  D∏ugotrwa∏e leczenie pamidronianem umiarkowanie ∏agodzi szpiczakowà chorob´ koÊci. W miar´ wyd∏u˝ania
leczenia wp∏yw pamidronianu na chorob´ koÊci staje si´ mniej wyraêny, a niedokrwistoÊç wyst´puje podobnie cz´sto jak
w grupie kontrolnej.
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Material and method
The study included 46 patients with multiple myeloma and
osteolysis hospitalised every month at the Department of
Haematology of the Institute of Haematology and Blood
Transfusion in Warsaw. Patient characteristics are presented in
the Table I. All patients received anti-myeloma chemotherapy
according to the VMCP/VBAP alternating regimen scheduled at
4 – week intervals. The patients were randomised to receive
either pamidronate (Aredia; Novartis) 60 mg i.v. in a 4-hour
infusion monthly (n=23) or chemotherapy alone (control group
n=23). Treatment with pamidronate was continued indefinitely.
The following parameters were estimated in each patient
at the trial entry and then at one-month intervals during
each hospitalization of the patient: performance status using
a 4-point scale (1 – normal, 2 – light work possible, 3 – up and
about >50% of the day, 4 – confined to bed), pain frequency and
pain severity using a 5-point scale (1 – none, 2 – mild, 3 – mo-
derate, 4 – severe, 5 – intolerable), analgesic drug use (1 – none,
2 – simple analgesic or NSAID, 3 – moderate analgesic, 4 –
opiates) [16], total and ionized serum calcium concentrations
as well as 24 – hour urine and two-hour fasting urine samples for
the excretion of calcium (the latter was expressed as ratio to
urinary creatinine and was measured during the first 24 months
of study). For comparative reasons fasting urinary calcium and
creatinine excretion were also determined in 11 healthy persons.
Hypercalcaemia was defined as albumin adjusted serum calcium
of >2.75 mmol/l. A complete X-ray skeletal survey including
long bone imaging was conducted at the entry point and then
every six months and was evaluated by a radiologist who was
blinded as to the treatment assignments. Assessment of X-ray
images was always performed by the same radiologist.
Progression of radiological changes was assessed on the basis of
either occurrence of new osteolytic foci or increase in size of
previously revealed changes. Comparison of size of osteolytic
foci included their direct measurement. X-ray survey was always
performed using the same X-ray equipment and the same films.
Changes from baseline in bone pain scores for analgesic
drug use, performance status scores, differences in calcium
concentrations and differences in Kaplan-Meier survival curves
were analyzed by Wilcoxon’s rank test. The number of patients
with skeletal complications and the number of complications
were compared by the Chi square test and Fisher’s exact test.
Results
All 46 patients included in this study were followed up
until death or for at least 6 years, except for 2 patients
who were lost to follow up at 7 months and 3 years,
respectively.
As it was illustrated in our previous publication
during the first months of treatment pain reduction was
greater in the pamidronate group than in the control
group (p<0.05). Beginning from the 9th month of
observation there were no differences in pain scores
between the compared groups [14].
During the study mean serum calcium concen-
trations remained within the range of normal values in the
pamidronate group (Table II).
Hypercalcaemia was observed in 6 patients at entry
point. In 5 of these patients pamidronate restored and
maintained normocalcaemia for a median of 6 months. In
3 patients aggressive plasma cell proliferation was
accompanied by reoccurrence of hypercalcaemia. The
incidence of hypercalcaemia episodes was lower in the
group of patients treated with pamidronate, as compared
to the control group, however the difference did not reach
statistical significance. 24-hour urinary calcium excretion
was increased (>6.25 mmol/24h) at the entry point in 8
patients in the pamidronate group. During pamidronate
treatment the value of this parameter returned to normal
in 6 patients, remained increased in 2 and was increased
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Table I. Clinical characteristics of patients at entry into the pamidronate study
Parameter Pamidronate Control
Sex M/F no. of patients 10 / 13 16 / 7
Age (yr) x ± SD 60 ± 10 66 ± 9
M- protein IgG/ IgA/ BJ/NS no. of patients 16 / 7 / 0 / 0 17 / 3 / 2 / 1
Stage D.S. II/ III no. of patients 0 / 23 1 / 22
Osteolysis no. of patients (%) 4 (17) 5 (21)
Vertebral fractures 2 (9) 2 (9)
Osteolysis + vertebral fractures 17 (74) 16 (70)
Hypercalcaemia >2.75 mmol/l no. of patients 5 2
Urine Ca/creat. ratio >0.3 mmol/l no. of patients 9 5
Serum creatinine <176 µmol/l no. of patients 23 23
Bone pain score no. of patients (%)
1-2 13 (57) 15 (65)
3-4 10 (43) 8 (35)
ECOG performance score no. of patients (%)
1 or 2 14 (65) 17 (74)
3 or 4 9 (35) 6 (26)
Time since MM diagnosis no. of patients (%)
<1 year 9 (39) 11 (48)
>1 year 14 (61) 12 (52)
Time since start of VMCP/VBAP therapy (mo)
– median 24 19
– mean 26 ± 22 26 ± 33
along with observed progression of disease in 2 patients.
Elevated values (>0.3) of urine Ca/creat ratios in 9
patients returned to normal during pamidronate
treatment; the Ca/creat. ratio was elevated in 1 patient,
normal in 8 patients before and during treatment, while in
5 patients the ratio values varied. In the control group
the Ca/creat. ratio varied, however in most cases it
exceeded 0.3.
Skeletal X-ray examination was performed after 6,
12, 18, 24, 30, 36, 42, 48, 54 and 66 cycles of pamidronate
– by comparing each consecutive imaging with the
previous one the progression of osteolysis was found in
67%, 39%, 27%, 20%, 25%, 25%, 60%, 80%, 92%, and
96% of patients respectively. In the control group the
corresponding ratios were 79%, 70%, 30%, 44%, 50%,
40%, 66% and 100% (p>0.16) (Table III).
Table III. Occurrence of progression of osteolysis* by the end
of cycle 6, 12, 18, 24, 30, 36, 42, 48, 54 and 66 of pamidronate
treatment
% of MM patients with progression of osteolysis
pamidronate control
6 cycles 67 79
12 cycles 39 70
18 cycles 27 30
24 cycles 20 44
30 cycles 25 50 p>0.16
36 cycles 25 40
42 cycles 60 66
48 cycles 80 100
54 cycles 92 N.D.
66 cycles 96 N.D.
* evaluated by comparing each consecutive skeletal X-ray imaging
with previous one
N.D. – not done
The mean number of skeletal events (pathologic
fracture, radiation or surgery to bone and spinal cord
compression) per year during the first 4 years of
treatment was 1.42 in the pamidronate group and 1.96
in the control group, while during further treatment it
was found to be 0.51 vs 0.9, respectively (p=0.08)
(Figure 1).
During the whole period of our study bone irra-
diation was performed in 4 patients from the pamidronate
group and in 2 patients from the control group.
Median time to the first skeletal-related event was 13
months in the pamidronate group and 7 months in the
control group. 
During the entire study period the proportion of
patients who developed skeletal events (excluding
vertebral fractures) was slightly lower in the pamidronate
group than in the control group – 52% vs 56% (p=0.42)
(Figure 2).
The ratios of patients with pathologic vertebral
fractures were similar – 76% vs 75%, respectively, but
the number of vertebral fractures was lower in the
pamidronate group, 50 vs 71 (1.2 vs 1.77 per year in the
first 4 years and 0.84 vs 0.91 in the next years of
treatment; p=0.07) (Figure 1).
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Table II. Calcium concentration in serum and urine at study onset and after 21 and 36 months (mo) of study
Baseline 21 mo 36 mo
Albumin adjusted serum calcium (mmol/l)
x ± SD
pamidronate 2.55 ± 0.22 2.21 ± 0.25 2.15 ± 0.23
control 2.43 ± 0.19 2.30 ± 0.28 2.22 ± 0.25
Urinary calcium excretion (mmol/24h)
x ± SD
pamidronate 4.01 ± 3.10 5.11 ± 2.90
control 5.27 ± 1.90 5.18 ± 2.00
healthy persons, range 2.50 – 6.25
Urinary calcium excretion mmol/ mmol urine creatinine
x ± SD (range)
pamidronate 0.61 ± 0.52 0.31 ± 0.28
control 0.41 ± 0.59 0.33 ± 0.38
healthy persons 0.11 ± 0.08
(0.03 – 0.30)
Figure 1. Number of bone related events including pathological
fracture, radiation to bone, spinal cord compression, orthopaedic
surgery and tumour induced hipercalcaemia per year in the
pamidronate group and the control group of multiple myeloma
patients after 48 cycles of therapy
In one patient treated with pamidronate we observed
“reconstruction” of pathologically fractured cervical
vertebrae after irradiation.
During the first 24 months of study decreases in
blood haemoglobin concentration were more frequent
in the pamidronate group than in the control group (72%
vs 41%, respectively) and mostly were accompanied by
progression of proliferation. (Table IV).
Table IV. Occurrence of anaemia in multiple myeloma patients during
long-term pamidronate treatment
Proportion of patients 
with Hb concentration <8.0 g/dl
pamidronate control p
After 21 cycles 72% 41% 0.04
After 36 cycles 72% 50% 0.23
After 53 cycles 40% 65% 0.18
Up to 66 cycles 60% 65% 0.49
The Kaplan- Meier survival curves did not differ in
the two studied groups (Figures 3, 4). Median survival
time from randomization was 21 months in the
pamidronate group and 20 months in the control group,
p=0.78 (Figure 3). Median survival time from multiple
myeloma diagnosis was 50 months in the pamidronate
group and 45 months in the control group, p=0.20. The
proportions of 5 and 8-year survival were 48% and 30%,
respectively, for those randomized to pamidronate, as
compared with 17% and 13%, respectively, in the
chemotherapy-only arm (Figure 4).
At the time of analysis 3 (12%) patients in the
pamidronate group and none in the control group
remained alive. In the pamidronate group 18 deaths
(95%) were considered to be myeloma-related while the
remaining one case was caused by cardiac disease. In the
control group 19 (86%) of the deaths were considered
to be myeloma-related. The causes of death of the
remaining 3 control patients included 1 from cerebro-
vascular incident, 1 from cardiac disease and 1 from
infection and diabetes. 
Table V. Survival of multiple myeloma patients treated with
pamidronate
Pamidronate Control
Median survival time 21 20
since randomization
(months) p=0.78
Median survival time 50 45
since MM diagnosis
(months) p=0.20
% of patients who died
(to March 2004) 87 100
Discussion
During the last decade the effect of treatment of
osteolytic myeloma–induced bone disease with
bisphosphonates was assessed in several studies [9, 10,
12, 16-24]. The core phase of the published clinical trials
on pamidronate efficacy in the treatment of myeloma
bone disease was confined to administration of the
analyzed drug over a period from several to 12 months,
whereas the extension phase (lasting till 24 months)
mainly referred to the assessment of patient survival time.
The trial reported here is the longest study of this
kind performed on myeloma patients in whom pamidro-
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Figure 2. Proportion of multiple myeloma patients experiencing bone
related events in the pamidronate group and the control group during
the entire study period
Figure 3. Kaplan-Meier estimates of survival from randomization in
the study patients
Figure 4. Kaplan-Meier estimates of survival from multiple myeloma
diagnosis in the study patients
nate treatment efficacy was assessed over a period of 8
years.
Our study on pamidronate (Aredia) at a dose of 60
mg i.v. administered every month as adjuvant myeloma
treatment commenced in 1995. In studies published
before its onset and devoted to the effect of the drug on
osteolytic bone disease pamidronate was administered at
a dose not exceeding 60 mg i.v. every month and only in
severe hypercalcaemia at a dose of 90 mg [25-27]. At that
time such a dose was suggested by the manufacturer.
More recent studies, which formed the base for pa-
midronate (Aredia) registration by the FDA in the US as
an adjuvant treatment of osteolytic bone disease
recommended its administration at a dose of 90 mg every
month [9].
As it was shown in our previous study [13, 14] and
also, to a certain extent, presented in this paper, in
patients receiving pamidronate we observed bone pain
reduction and an improvement of bone turnover indices.
However, the reduction of clinical symptoms related to
bone destruction was greater in patients treated with
pamidronate as compared to the control group only in
the first 8 months of treatment. Pamidronate admini-
stration was associated with an insignificant decrease in
the proportion of patients with hypercalcaemia, but the
mean serum calcium concentration remained in the
normal limits during the entire study time (Table II).
Despite the administration of combined treatment,
i.e. chemotherapy and pamidronate, the frequency of
osteolysis progression reached 67% during the first six
months of treatment. The beneficial effect of pamidronate
on bone pathology became evident after twelve months of
treatment as a lower rate of patients with further osteo-
lysis progression (39% of patients in the pamidronate
group versus 70% in the control group) as well as by
a lower skeletal morbidity rate (SMR) = skeletal related
events per year (1.82 versus 2.72) and the proportion of
patients who developed a skeletal event (34% vs 52%)
[14]. Median time to the first skeletal-related event was 13
months in the pamidronate group and 7 months in the
control group. No differences were found in the frequency
of osteolysis progression between the two groups after
24 cycles of therapy (p>0.16) (Table III). In the two
further consecutive years of the trial the difference in the
incidence of bone complications between the two groups
diminished (SMR for the pamidronate group – 1.42; for
the control group – 1.96) but it remained apparent over
the next years; the SMRs for extravertebral complications
amounted to 0.51 and 0.91 respectively. By the end of
the 8-year study period the combined proportions of
patients experiencing bone complications were similar in
the pamidronate group and in the control group: 52% vs
58% for extravertebral complications and 76% vs 75%
for vertebral fractures. A significant survival advantage
has not been shown (Figures 3, 4, Table V).
The outcomes of pamidronate efficacy in multiple
myeloma in respect to incidence of skeletal events and
bone pain achieved in our first 21-month-study are nearly
convergent with those from Berenson’ s et al. trial [9, 10]
so far the largest study on intravenous pamidronate
effectiveness in myelomatosis.
In the study of Berenson et al. [9] 392 stage III
multiple myeloma patients with osteolysis were rando-
mized to receive either pamidronate at a dose of 90 mg or
placebo, both in 4 – hour intravenous infusions admini-
stered every four weeks and combined with anti-tumor
chemotherapy. Results presented in 1996, after the
administration of 9 cycles, showed a remarkable decrease
in the ratio of patients experiencing bone fractures and
requiring orthopedic-surgical management and radio-
therapy in the pamidronate group (24% vs 41%), as well
as a significant decrease in the ratio of patients with
hypercalcaemia episodes during the first three months
of treatment (1% vs 5%). Pamidronate treatment
provided significant improvement of bone pain, decreases
in anti-analgesic drugs consumption and improvement
of the quality of life. In 150 patients the treatment with
pamidronate was continued and 41% of them received 21
cycles of therapy, after which the authors observed
a decrease both in the proportion of patients experiencing
various bone complications and in the number of bone
complications. Among all the 392 patients no differences
were found in overall survival between the pamidronate
and placebo group, whereas the median survival of
patients enrolled into the study during second – or greater
– line chemotherapy programs was 21 months for patients
receiving pamidronate and 14 months for patients
receiving placebo.
It is noteworthy that in another large trial – 167
enrolled patients with Durie-Salmon stage III multiple
myeloma and osteolysis treated with 90 mg of pamidro-
nate via intravenous infusion every 3 to 4 weeks for 12
months, 49% of patients experienced at least one skeletal
related event, SMR was 1.43 and the median time to the
first skeletal related event was 363 days from study entry
[17]. The authors have offered a possible explanation for
the larger proportion of myeloma patients with a skeletal
related event, as compared to the figures in the previously
reported pamidronate studies – myeloma patients in this
trial [17] were enrolled much earlier after diagnosis than
those in the previous trials (3 months, as compared to
15 months) [9, 10]. Clinical experience shows that patients
newly diagnosed with multiple myeloma go through
a period of increased risk of fracture until their primary
chemotherapy begins to take effect.
A large, international, randomized trial designed to
directly compare the efficacy and safety of 4 or 8 mg of
zoledronic acid with 90 mg of pamidronate has shown
that pamidronate was as effective as zoledronic acid in
reducing the risk of skeletal complications in multiple
myeloma patients with osteolysis [17-20].
Terpos et al. [12] have compared the effect of
pamidronate (90 mg) and ibandronate (4 mg) in monthly
intravenous infusions on bone remodelling and disease
activity in multiple myeloma. In both groups the com-
bination of chemotherapy with either pamidronate or
ibandronate produced a reduction in bone resorption
and tumour burden. However, they observed a greater
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reduction in serum concentration of biochemical markers
of bone resorption (NTX, TRACP-5b), IL-6 and beta2-
microglobulin in the pamidronate group than in the
ibandronate group. There was no difference in the
occurrence of skeletal events during the 10 months of
follow-up. On the other hand a recent randomized,
double blind, placebo controlled trial failed to show any
effect of 2.0 mg of ibandronate on bone morbidity
reduction or on prolongation of survival in multiple
myeloma [21].
In the Brincker et al. [22] trial, 304 multiple myeloma
patients were randomised to receive either oral pami-
dronate at a dose of 300 mg/d. or placebo, in addition to
conventional treatment. It was found that pamidronate
showed no effect on skeletal morbidity. The negative
result of this study was attributed to the very low
absorption of orally administered bisphosphonates. 
The Medical Research Council (VIth Myeloma
Study) in the UK has performed the largest trial on
clodronate in multiple myeloma [23]. In addition to
chemotherapy (acc. to ABCM, ABCMP), 536 newly
diagnosed patients were randomised to receive either
oral clodronate (1600 mg/d) or placebo. After one year of
follow-up, the percentage of non-vertebral fractures was
13.2% in the placebo group and 6.8% in the clodronate
group (p=0.036). Vertebral fractures were also less
frequent in the clodronate group, than in the placebo
group (38% vs 55%; p<0.001). At 2 years, the patients
who received clodronate had a better performance status
and experienced lesser back pain than those treated with
placebo. Although there was no difference in overall
survival between the two groups (34 months vs 36
months), in the subgroup of 153 patients with no skeletal
fractures at presentation there was observed a significant
survival advantage (p=0.006) in favour of 73 patients
receiving clodronate; median survivals were, respectively,
59 months and 37 months, and proportions of 5-year
survivals – 46% and 35% (24).
We would like to stress the appearance of recon-
struction of vertebrae destroyed by the osteolytic process
in one patient on supportive treatment with pamidronate
and irradiation [28]. Regeneration of bone lesions in
multiple myeloma is extremely unusual – perhaps
bisphosphonates may promote the occurrence of this
phenomenon [20].
A previously published report included the early
adverse events of pamidronate administration [13]. In
our further studies on the assessment of long-term
pamidronate treatment attention was drawn to the more
frequent occurrence of anaemia in the pamidronate group
than in the control group (72% vs 41% after 21 cycles of
pamidronate) [14]. A higher incidence of anaemia in
patients treated with pamidronate was also observed by
Berenson et al. [10]. Although the reason for such
a phenomenon remains unclear it should be stressed that
the appearance of anaemia in our patients was usually
associated with proliferation progression and in the later
period of treatment the difference in incidence of
anaemia between pamidronate group and controls tended
to disappear (Table IV).
Bisphosphonates are widely administered in the
management of myeloma-associated hypercalcaemia,
however their exact clinical role in multiple myeloma
remains unclear. In order to summarize the available
knowledge concerning advantages and disadvantages of
bisphosphonate application in multiple myeloma the
Cochrane Myeloma Review Group performed a meta-
analysis based on 11 trials that included 2183 assessable
patients: 1113 patients treated with bisphosphonates and
1070 controls. The meta-analysis demonstrated a bene-
ficial effect of both intravenous pamidronate and
clodronate on the prevention of pathological vertebral
fractures (p=0.0003), on the prevention of hyper-
calcaemia (p=0.0001), and on the experienced pain,
(p=0.0001). The analysis of bisphosphonate effect on
pain was based on clinically heterogenous data and must
be interpreted with caution. In the absolute terms, the
results may be interpreted as follows: 10 patients with
multiple myeloma should be treated to prevent one
vertebral fracture, 19 to prevent one patient from
developing hypercalcaemia and 7 to prevent one patient
from experiencing pain [29, 30].
The American Society of Clinical Oncology con-
vened an Expert Multidisciplinary Panel under the
auspices of its Health Services Research Committee to
develop recommendations regarding the use of bisphos-
phonates for multiple myeloma. The Panel reviewed
pertinent information from the published literature
through January 2002 and concluded: Bisphosphonates
provide a meaningful supportive benefit to multiple
myeloma patients with lytic bone disease. However,
further research on bisphosphonates should answer the
following questions: 1) when to start and stop therapy,
2) how to integrate their use with other treatments for
lytic bone disease, 3) how to evaluate their role in
myeloma patients without lytic bone involvement, 4) how
to distinguish between symptomatic and asymptomatic
bone events, and 5) how to better determine their cost –
benefit consequence [31].
Conclusions
Long-term monthly intravenous pamidronate admini-
stration as an adjunct to chemotherapy in patients with
advanced multiple myeloma and osteolysis moderately
reduces skeletal morbidity, but does not significantly
prolong survival. When treatment duration is extended
the effect of pamidronate on skeletal morbidity becomes
less pronounced and the difference in the incidence of
anaemia between the pamidronate group and the control
group tends to disappear.
Prof. Maria Kraj MD, PhD
Department of Haematology
Institute of Haematology and Blood Transfusion
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